Anti-IGF1R Recombinant Antibody (TAB-736)

Customer Review

There are currently no Customer reviews or questions for TAB-736. Click the button above to contact us or submit your feedback about this product.

Laura Brown
03.Dec,23

Ideal for IGF1R Research

The Anti-IGF1R Therapeutic Antibody (dalotuzumab) has been excellent for our IGF1R research. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Emily Lewis
09.Aug,22

Reliable in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for IGF1R is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

John Carter
26.Sep,21

Consistent and Effective

This antibody has proven to be consistent and effective in our various assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for IGF1R have been particularly beneficial.

Q&As

1. Is the anti-IGF1R therapeutic antibody Dalotuzumab suitable for use in Western blotting?

   A: Yes, the anti-IGF1R therapeutic antibody Dalotuzumab (TAB-736) is suitable for use in Western blotting. It provides specific binding to IGF1R, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-IGF1R therapeutic antibody Dalotuzumab?

   A: The recommended storage condition for the anti-IGF1R therapeutic antibody Dalotuzumab (TAB-736) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-IGF1R therapeutic antibody Dalotuzumab be used in immunoprecipitation assays?

   A: Yes, the anti-IGF1R therapeutic antibody Dalotuzumab (TAB-736) can be used in immunoprecipitation assays. It provides specific binding to IGF1R, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-IGF1R therapeutic antibody Dalotuzumab effective in ELISA applications?

   A: Yes, the anti-IGF1R therapeutic antibody Dalotuzumab (TAB-736) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of IGF1R.

5. What is the optimal dilution for using the anti-IGF1R therapeutic antibody Dalotuzumab in immunofluorescence?

   A: The optimal dilution for using the anti-IGF1R therapeutic antibody Dalotuzumab (TAB-736) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Chew, Hui Yi, et al. "Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies." Cell 180.5 (2020): 895-914. https://doi.org/10.1016/j.cell.2020.02.019
   This study explores the use of prochlorperazine (PCZ) to inhibit endocytosis in vivo and enhance the efficacy of therapeutic antibodies targeting cancers. The researchers conducted both preclinical and clinical studies to evaluate the potential of PCZ to block endocytosis temporarily, thereby increasing the availability and effectiveness of antibodies such as cetuximab and trastuzumab on the surface of tumor cells. The study demonstrated that PCZ treatment could significantly enhance antibody-dependent cellular cytotoxicity (ADCC) and improve the therapeutic outcomes in head and neck squamous cell carcinoma (HNSCC) models.
   Creative Biolabs provided humanized monoclonal antibodies for this study, specifically targeting HER3 and IGF-1R. The products included lumretuzumab (Cat# TAB-H47) and dalotuzumab (Cat# TAB-736). These antibodies were used at a final concentration of 60 μg/mL for immunofluorescence and ADCC assays. Lumretuzumab and dalotuzumab played a critical role in the study's examination of antibody internalization and antibody-dependent cellular cytotoxicity (ADCC) in various cancer cell lines, allowing researchers to assess the therapeutic potential and efficacy of these targeted treatments.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-736, RRID: AB_3111996)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Dalotuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Dalotuzumab.

Related Signaling Pathways

Insulin Signaling Pathway

Related Diseases

Endocrine Resistance

Type I Diabetes Mellitus

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "IGF1R"

Select a product category from the dropdown menu below to view related products.